Table 3 Comparison of clinical factors with CXCL14 for stage I/II patients and stage III/IV patients
Clinical Factors | CXCL14 Expression (stage I/II) | CXCL14 Expression (stage III/IV) | ||||
|---|---|---|---|---|---|---|
Low (n = 9) | High (n = 22) | P value | Low (n = 68) | High (n = 67) | P value | |
Sex | 0.599※ | 0.543※ | ||||
Female | 27 (29.7%) | 10 (11.0%) | 34 (25.2%) | 37 (27.4%) | ||
Male | 42 (46.2%) | 12 (13.2%) | 34 (25.2%) | 30 (22.2%) | ||
Age | 0.878†| 0.878†| ||||
Mean ± SD | 62.4 ± 13.5 | 63.7 ± 14.1 | 58.7 ± 14.7 | 59.5 ± 14.0 | ||
Median | 65 | 64 | 61 | 62 | ||
Range | 25–88 | 35–82 | 25–84 | 29–88 | ||
TNM stage | 0.674∮ | 0.165∮ | ||||
p I | 7 (7.7%) | 1 (1.1%) | ||||
p II | 62 (68.1%) | 21 (23.1%) | ||||
p III | 66 (48.9%) | 61 (45.2%) | ||||
p IV | 2 (1.5%) | 6 (4.4%) | ||||
Tumor invasion | 0.123∩ | 0.522∩ | ||||
pT1 | 1 (1.1%) | 0 (0%) | ||||
pT2 | 6 (6.6%) | 1 (1.1%) | 2 (1.5%) | 2 (1.5%) | ||
pT3 | 59 (64.8%) | 18 (19.8%) | 64 (47.4%) | 61 (45.2%) | ||
pT4 | 3 (3.3%) | 3 (3.3%) | 2 (1.5%) | 4 (3.0%) | ||
Lymph node No./metastasis | 0.348∩ | 0.78∩ | ||||
0-7/pN0 | 20 (22.0%) | 5 (5.5%) | 2 (1.5%) | 6 (4.4%) | ||
8–12/pN1 | 37 (40.7%) | 12 (13.2%) | 56 (41.5%) | 49 (36.3%) | ||
>12/pN2 | 12 (13.2%) | 5 (5.5%) | 10 (7.4%) | 12 (8.9%) | ||
Grade | 0.246∩ | 0.05∩ | ||||
Well | 21 (23.1%) | 7 (7.7%) | 20 (14.8%) | 9 (6.7%) | ||
Moderate | 42 (46.2%) | 8 (8.8%) | 44 (32.6%) | 46 (34.1%) | ||
Poor | 6 (6.6%) | 7 (7.7%) | 4 (3.0%) | 12 (8.9%) | ||
Tumor size, cm | 0.001∩ | 0.002∩ | ||||
<2 | 20 (22.0%) | 0 (0%) | 26 (19.3%) | 11 (8.1%) | ||
2-5 | 45 (49.5%) | 18 (19.8) | 34 (25.2%) | 38 (28.1%) | ||
>5 | 4 (4.4%) | 4 (4.4%) | 8 (5.9%) | 18 (13.3%) | ||
Location | 0.100※ | 0.191※ | ||||
Colon | 27 (29.7%) | 13 (14.3%) | 34 (25.2%) | 41 (30.4%) | ||
Rectum | 42 (46.2%) | 9 (9.9%) | 34 (25.2%) | 26 (19.3%) | ||